Growth of all business sectors including chemicals and biopharmaceuticals
viewer
Celltrion Pharmaceutical (068760)Since 2009, when it joined the Celltrion Group, it achieved the highest performance ever recorded last year.
Celltrion Pharmaceutical announced on the 25th that based on the consolidated financial statements in 2020, sales increased by 34.6% over the same period last year to KRW 233.6 billion, and operating profit during the same period increased by 60.3% to KRW 23.6 billion. Net income increased by 143.4% to 20.9 billion won. Sales, operating profit, and net profit are all-time highs since 2009, when it was incorporated into the Celltrion Group.
Celltrion Pharmaceutical explained that the growth of all business divisions, including chemicals and biopharmaceuticals, drove sales. An official at Celltrion Pharmaceutical explained, “The global chemical product sales, which expanded in earnest from the third quarter of last year, were effective.” Celltrion Pharmaceutical’s flagship product, Godex, a soy sauce solvent, recorded sales of about 65.7 billion won, the largest single item. The sales of three antibody biosimilars, Remsima, Hezuma, and Truxima, also recorded about 43.3 billion won, a growth of about 14% year-on-year. In addition, six kinds of global chemical drugs, including CT-G7, a human immunodeficiency virus (HIV) treatment, increased production and shipments, achieving sales of about 43 billion won.
In the future, Celltrion Pharmaceutical plans to maximize the production efficiency of major items and focus on expanding its earnings by reinforcing marketing. Preparation and management of new growth engines are also thoroughly continued. It is also spurring preparations for operation of the Prefilled Syringe (PFS) line for the production of subcutaneous injection formulations. An official at Celltrion Pharmaceutical said, “We specialize in items newly incorporated into the product lineup, such as’Lee Dalbi’,’Nesina’,’Actos’,’Fight Ben’, and’Albochill’, which secured sales rights at the end of last year. We plan to reinforce our targeting in the pharmaceutical (ETC) and over-the-counter (OTC) markets.” He explained. “This year, as we have secured a number of promising products such as’Remsima SC’, a new diabetes treatment, and high blood pressure treatment, we expect to continue to a higher level of growth based on product competitiveness.” “We will do our best to continue steadily growing in various areas other than the liver disease treatment area.”
/ Reporter Kim Seong-tae [email protected]
< 저작권자 ⓒ 서울경제, 무단 전재 및 재배포 금지 >